Invention Grant
- Patent Title: Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
-
Application No.: US15354053Application Date: 2016-11-17
-
Publication No.: US10195203B2Publication Date: 2019-02-05
- Inventor: Thomas Klein , Maximilian von Eynatten , Michael Mark
- Applicant: Boehringer Ingelheim International GmbH
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringr Ingelheim International GmbH
- Current Assignee: Boehringr Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent David L. Kershner
- Priority: EP12167953 20120514; EP12170888 20120605; EP12006812 20120928; EP12190447 20121029
- Main IPC: A61K38/13
- IPC: A61K38/13 ; A61K31/522 ; C07D473/06 ; A61K45/06 ; A61K31/155 ; A61K31/18 ; A61K38/28
Abstract:
The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
Public/Granted literature
- US20170065595A1 USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME Public/Granted day:2017-03-09
Information query
IPC分类:
